
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is in a strong position with its promising drug candidates GRI-0621 and GRI-0803 addressing high unmet needs in serious diseases. Despite a long development timeline and the inherent risks in the biotech industry, the potential billion-dollar market for GRI Bio's therapies presents high rewards. The company's recent fiscal Q1 2026 results were in line with expectations and it has a strong focus on developing treatments for idiopathic pulmonary fibrosis, a rapidly growing market affecting a significant number of patients. However, as a clinical stage company, GRI Bio currently generates no revenue and its financials will heavily depend on the success of its drug candidates in clinical trials and commercialization.
Bears say
GRI Bio is facing several potential risks, including balance sheet and liquidity issues, failure to gain regulatory approvals and suitable reimbursement for their product candidates. Additionally, competition in the biotech industry may hinder the company's ability to commercialize its products and changing macroeconomic factors, as well as investor sentiment, may also impact its success. The company's focus on developing GRI-0621 for IPF treatment is promising, but if the product fails to demonstrate safety and efficacy in clinical trials, it could negatively affect the company's overall outlook.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares